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Summary
 
The urokinase receptor (CD87; uPAR) is found in close association with 
 
b
 
2
 
 integrins on leu-
kocytes. We studied the functional consequence of this association for leukocyte adhesion and
migration. In vivo, the 
 
b
 
2
 
 integrin–dependent recruitment of leukocytes to the inflamed peri-
toneum of uPAR-deficient mice was significantly reduced as compared with wild-type ani-
mals. In vitro, 
 
b
 
2
 
 integrin–mediated adhesion of leukocytes to endothelium was lost upon re-
moval of uPAR from the leukocyte surface by phosphatidyl-inositol–specific phospholipase C.
Leukocyte adhesion was reconstituted when soluble intact uPAR, but not a truncated form
lacking the uPA-binding domain, was allowed to reassociate with the cell surface. uPAR liga-
tion with a monoclonal antibody induced adhesion of monocytic cells and neutrophils to vas-
cular endothelium by six- to eightfold, whereas ligation with inactivated uPA significantly re-
duced cell-to-cell adhesion irrespective of the 
 
b
 
2
 
 integrin–stimulating pathway. These data
indicate that 
 
b
 
2
 
 integrin–mediated leukocyte–endothelial cell interactions and recruitment to
inflamed areas require the presence of uPAR and define a new phenotype for uPAR-deficient
mice. Moreover, uPAR ligation differentially modulates leukocyte adhesion to endothelium and
provides novel targets for therapeutic strategies in inflammation-related vascular pathologies.
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eukocyte activation and adhesion to the endothelium
and the subsequent transendothelial migration are piv-
otal steps in the recruitment of cells to inflamed tissue. This
highly coordinated multistep process requires tight regula-
tion (1, 2). This includes the induction of genes coding for
adhesion molecules and the modification of ligand-binding
affinities of adhesion receptors on leukocytes as well as their
change in avidity due to adhesion receptor clustering of
leukocytes. Uncontrolled activation of leukocytes or en-
dothelial cells leads to pathological chronic inflammation
causing atherosclerosis, rheumatoid arthritis, and other dis-
ease states.
The 
 
b
 
2
 
 integrin family of adhesion receptors consists of
the four members, LFA-1 (
 
a
 
L
 
b
 
2
 
, CD11a/CD18),
 
1
 
 Mac-1
(
 
a
 
M
 
b
 
2
 
, CD11b/CD18, CR3), p150,95 (
 
a
 
X
 
b
 
2
 
, CD11c/
CD18), and 
 
a
 
D
 
b
 
2
 
 (CD11d/CD18) (3, 4). In acute inflam-
mation, LFA-1 and Mac-1 are the predominant 
 
b
 
2
 
 inte-
grins mediating leukocyte adhesion to vascular endothe-
lium. Mac-1 is constitutively expressed on neutrophils and
monocytes, whereas LFA-1 is predominantly expressed on
lymphocytes, but recent data underline its important con-
tribution in neutrophil recruitment (5, 6). Leukocyte acti-
vation via cytokines, chemoattractants, or PMA induces
both conformational changes in 
 
b
 
2
 
 integrins necessary for
enhanced ligand recognition and translocation of Mac-1 to
the cell surface (2, 7). Likewise, integrin activation is
achieved extracellularly in vitro by the divalent cation
Mn
 
2
 
1
 
 (8). After activation, Mac-1 and LFA-1 firmly bind
to intercellular adhesion molecule (ICAM)-1 (CD54) ex-
pressed on vascular endothelial (1) and smooth muscle cells
(9). 
 
b
 
2
 
 integrins have been reported to form complexes
with other plasma membrane proteins such as CD63 (10),
the immunoglobulin receptor Fc
 
g
 
RIIIB (CD16b) (11) and
the urokinase receptor (uPAR, CD87) (12, 13) suggesting
possible functional interaction.
uPAR consists of three homologous domains and is an-
chored to the plasma membrane by a glycolipid moiety that
 
1
 
Abbreviations used in this paper:
 
 HUVEC, human umbilical vein endothe-
lial cells; HVSMC, human vascular smooth muscle cells; ICAM-1, inter-
cellular adhesion molecule 1; LFA-1, 
 
a
 
L
 
b
 
2
 
 integrin (CD11a/CD18);
Mac-1, 
 
a
 
M
 
b
 
2
 
 integrin (CD11b/CD18); ns, not significant; piPLC, phos-
phatidyl-inositol–specific phospholipase C; uPA, urokinase (urinary-type
plasminogen activator); uPAR, urokinase receptor.
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is susceptible to dissociation by phosphatidyl-inositol–
specific phospholipase C (piPLC) (14). Intact uPAR binds
the protease uPA (urinary-type plasminogen activator) as
well as the adhesive protein vitronectin with high affinity
(15), and thereby plays a critical role in pericellular proteol-
ysis and modulation of cellular contacts in adhesion and
migration (16, 17). Although uPAR lacks its own trans-
membrane and cytoplasmic domain, uPA binding has been
reported to transduce signals to the cell interior in leuko-
cytes resulting in calcium mobilization (18), protein kinase
phosphorylation (12, 19–21), and other cellular effects (18,
21, 22). For some of these functions, it has been suggested
that uPAR uses related transmembrane integrins as signal
transduction devices (23). In fact, uPAR has been localized
together with different integrins in focal adhesion areas
(24), and increased uPAR expression and localization of
the receptor to the leading edge of migrating monocytes
appears to be essential for locomotion or invasiveness of
cells independent of uPA activity (20, 25). It has been
shown in vitro that uPAR crucially influences integrin
function (26): the presence of uPAR inhibited 
 
b
 
1
 
 integrin–
mediated cell binding to fibronectin, whereas uPAR favored
 
b
 
2
 
 integrin–dependent monocyte adhesion to fibrinogen,
one of the adhesive ligands of Mac-1. Moreover, using
uPA antisense or ligation with uPA inhibited Mac-1 bind-
ing to and degradation of fibrinogen (27, 28). Based on
these studies, uPAR has been proposed to form a func-
tional unit with integrins on the cell surface.
These relationships prompted us to investigate the con-
tribution of uPAR in 
 
b
 
2
 
 integrin–mediated cell-to-cell in-
teractions in vivo using uPAR knockout mice, as well as in
vitro,
 
 
 
to elute the mechanism of receptor cross-talk. Evi-
dence is provided that uPAR is required for 
 
b
 
2
 
 integrin–
dependent leukocyte adhesion and recruitment.
 
Materials and Methods
 
Materials
 
Manganese chloride was obtained from Sigma Chemical Co.
(Munich, Germany) and PMA from GIBCO BRL (Paisley, Scot-
land). piPLC was from Oxford Glyco-Systems (Abingdon, UK).
Intact recombinant soluble uPAR as well as the chymotrypsin-
cleaved truncated form lacking domain 1 were produced as previ-
ously described (29, 30) and were provided by Dr. Niels Behrendt
(Finsen Laboratory, Copenhagen, Denmark). uPA (Medac, Ham-
burg, Germany) was inactivated by diisopropyl-fluorophosphate
(Serva, Heidelberg, Germany) as previously described (31).
 
Antibodies
 
The following mouse anti–human uPAR mAbs were used in
vitro. mAb no. 3936 (IgG2a-type), provided by Dr. Richard Hart
(American Diagnostica, Greenwich, CT), is known to block uPA
binding by recognizing an epitope of uPAR that has not been
clearly identified yet (32). (Fab
 
9
 
)
 
2
 
 fragments were generated using
digestion by immobilized pepsin followed by protein A–Sepharose
affinity chromatography (Pierce Chemical Co., Rockford, IL).
Purity was controlled by polyacrylamide gel-electrophoretic anal-
ysis. mAbs R3 and R9, which recognize domain 1 and interfere
 
with uPA binding, and mAbs R2, R4 and R8, which recognize
domain 2 and 3 without influencing uPA binding, were provided
by Dr. Gunilla Hoyer-Hansen (Finsen Laboratory, Copenhagen,
Denmark). The characteristics of mAbs R2, R3, R4, R8, and R9
have been described previously (33). Mouse anti–human 
 
b
 
2
 
 chain
(CD18) mAb 60.3 (IgG2a-type) blocks 
 
b
 
2
 
 integrin–mediated leu-
kocyte adhesion to endothelium (34) and was provided by Dr.
John Harlan (Harborview Medical Center, Seattle, WA). Mouse
anti–human IgG2a (Sigma Chemical Co.) was used as isotype-
matched control antibody. When necessary, fluorescein-conju-
gated mouse mAbs anti-CD11a (no. 25.3), anti-CD11b (Bear 1),
and anti-CD18 (no. 7E4) (Immunotech, Hamburg, Germany)
were used for flow cytometry.
The following reagents were used in animal experiments. R-PE-
labeled streptavidin (Southern Biotechnology Associates, Inc.,
Birmingham, AL) and biotin-conjugated rat anti–mouse CD11b
(M1/70), Ly-6G (Gr-1) (RB6-8C5), and CD3e (145-2C11) (all
from PharMingen, San Diego, CA). Anti-
 
a
 
L
 
b
 
2
 
 integrin (CD11a)
(FD 441.8) (35) and YN1.1 (36) (American Type Culture Col-
lection, Rockville, MD) were affinity purified and dialyzed under
endotoxin-free conditions.
 
Cells
 
Human myelo-monocytic HL60 and U937 cell lines (German
Collection of Microorganisms and Cell Cultures, Braunschweig,
Germany) were cultured in RPMI 1640 supplemented with 10%
(vol/vol) fetal calf serum, 1% sodium pyruvate, 1 mM 
 
l
 
-glutamine,
100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin (all from
GIBCO BRL). 24 h before experiments, monocytic differentia-
tion was induced by addition of 50 ng/ml 1
 
a
 
,25-dihydroxyvita-
min D3 and 1 ng/ml transforming growth factor 
 
b
 
1 (Biomol,
Hamburg, Germany). Peripheral blood PMNs were isolated by
discontinuous density gradient centrifugation using Histopaque-
1119 and -1077 (Sigma Chemical Co.) as described by the manu-
facturer. An enrichment of at least 95% neutrophils was obtained
as controlled by flow cytometry using forward and side scatter
analysis and staining for CD15. Human umbilical vein endothelial
cells (HUVECs), provided by Dr. Bernd Pötzsch (Kerckhoff-
Klinik), were isolated as previously described (37) and cultured
(for 2–4 passages) in low serum endothelial cell growth medium
(PromoCell, Heidelberg, Germany) on gelatin-coated tissue-cul-
ture plastic. Human vascular smooth muscle cells (HVSMCs)
were isolated from aorta or saphenous vein by the explant method
and characterized as previously described (38). Early passage cells
were cultured in smooth muscle cell medium (PromoCell).
 
Peritonitis Assay
 
Peritonitis was induced in female uPAR
 
2/2
 
 (39) or wild-type
mice by intraperitoneal injection of a solution of 4% (wt/vol) in
Bacto Fluid Thioglycollate Medium (Difco Labs., Detroit, MI).
Endotoxin-free stock solutions were prepared at 100
 
8
 
C and sub-
sequently heat-sterilized.
Mice obtained by shipping were generally kept (at the Basel
Institute for Immunology) for at least 2 wk before the start of ex-
periments to relieve stress. PBS alone or antibodies against
ICAM-1, LFA-1 (200 
 
m
 
l of a 1 mg/ml solution each) were in-
jected intravenously into the tail vein 30 min before induction of
peritonitis. All reagents were endotoxin-free. After 4 or 24 h, re-
spectively, mice were killed and peritoneal cells were suspended
by injection of 5 ml PBS containing 2 mM EDTA and 50 
 
m
 
g/ml
heparin into the peritoneum. The loaded mouse was shortly mas-
saged and 4 ml of this lavage were collected and leukocytes were 
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counted on a Coulter counter ZM equipped with a channelizer
256 (Coulter Corp., Miami, FL). Animal studies were approved
by the Institutional Review Board.
 
Adhesion Assays
 
HUVECs were seeded in gelatin-coated 48-well plates (Cos-
tar, Badhoevedorp, The Netherlands) 48 h before the experi-
ment. Confluency was confirmed by microscopic inspection be-
fore each experiment. HL60 or U937 cells were radiolabeled
with 1 
 
m
 
Ci/ml methyl-[
 
3
 
H]thymidine (Nycomed Amersham,
Little Chalfont, Buckinghamshire, UK) for 24 h and differenti-
ated to monocytic cells (see above) for another 24 h. These
monocytic cells or freshly isolated neutrophils were washed twice
in adhesion medium (serum-free RPMI 1640/Hepes 25 mM),
followed by different pretreatments (see figure legends for details),
and were added (7 
 
3 
 
10
 
5
 
/ml adhesion medium) to the prewashed
HUVEC monolayers in the presence or absence of the blocking
mAb anti–
 
b
 
2
 
 integrin or isotype IgG (final concentration 10 
 
m
 
g/
ml). After 30 min of coincubation (37
 
8
 
C, 5% CO
 
2
 
, 90% humid-
ity), the plates were gently washed twice with adhesion buffer to
remove nonadherent cells. Remaining adherent cells were lysed
with 1 M NaOH and quantitated in a beta counter. When flow
cytometry was performed in parallel to neutrophil adhesion, the
number of adherent cells in 10 high power fields was counted us-
ing light microscopy. At least triplicate wells were run per test
substance, and results are expressed as mean values 
 
6 
 
SEM. The
experimental protocol for cell adhesion to HVSMCs, which were
seeded 7–9 d before the assay, was identical.
 
Flow Cytometry
 
Animal Model.
 
The mouse leukocyte subpopulations were
further analyzed by flow cytometry (Becton Dickinson, Heidel-
berg, Germany) using the biotin-coupled anti–mouse CD11b
(integrin 
 
a
 
M chain, Mac-1), anti–Gr-1 (anti-myeloid differentia-
tion antigen Gr-1), or anti-CD3 (anti-CD3 TCR-associated
complex). Fc receptors of leukocytes were blocked by preincuba-
tion of the cells for 30 min with 5% (vol/vol) rat and 5% (vol/
vol) mouse serum in PBS. The secondary reagent PE-coupled
streptavidin (dilution of 1:2,500) was incubated with the cells for
30 min.
 
In Vitro System.
 
Cells (2.5 
 
3 
 
10
 
5
 
) were washed twice with
Hepes-buffered saline and incubated with primary mouse anti–
human antibodies for 30 min on ice (for CD11b detection at
21
 
8
 
C). Cells were washed again and resuspended in Hepes buffer
containing fluorescein-conjugated (Fab
 
9
 
)
 
2
 
 fragment of goat anti–
mouse IgG (Dianova, Hamburg, Germany). To test the effect of
mouse antibodies on 
 
b
 
2
 
 integrin expression, fluorescein-conju-
gated mAbs at a dilution of 1:50 were used. Mean fluorescence of
5,000 cells was measured in a flow cytometer (Becton Dickin-
son). Nonspecific fluorescence was determined using an isotype-
matched mouse IgG as the primary antibody.
 
Statistical Analysis
 
Comparisons between group means were performed using
multivariant analysis (ANOVA). Data represent mean 
 
6
 
 SEM;
 
P 
 
, 
 
0.05 was regarded as significant.
 
Results
 
Leukocyte Emigration in uPAR-deficient Mice.
 
Transendo-
thelial migration of leukocytes to inflamed tissue depends
on the interaction of the leukocyte with the vascular en-
dothelium by 
 
b
 
2
 
 integrins and ICAM-1. Thioglycollate-
induced peritonitis is a reliable model to test leukocyte emi-
gration into sites of acute inflammation. Disruption of the
mouse ICAM-1–
 
b
 
2
 
 integrin interactions resulted in re-
duced leukocyte emigration in this model when compared
with wild-type animals (40). Both uPAR-deficient and
wild-type animals of the identical genotype (129 
 
3 
 
C57/
BL6 F1) were compared for leukocyte emigration in the
peritonitis model. The number and types of leukocytes in
the peripheral blood were identical in both sets of mice
(data not shown). Lavages performed 4 (Fig. 1) and 24 h
(data not shown) after induction of peritonitis showed
 
z
 
50% reduction in counts of the total leukocyte popula-
tion in uPAR-deficient mice when compared with wild-
type animals (Fig. 1). When animals were treated with
anti–ICAM-1 or anti–LFA-1 antibodies at the time of in-
duction of peritonitis, the number of emigrating leukocytes
was further reduced by 50% in wild-type mice, but by only
30% in uPAR-deficient animals, suggesting that a major
part of the initial lack of emigration was due to a perturbed
 
b
 
2
 
 integrin/ICAM-1 function. Analysis of the leukocyte
subpopulations by flow cytometry using specific markers as
indicated in Materials and Methods revealed that in uPAR-
deficient mice granulocytes almost totally lost their ability
to migrate into the peritoneum after 4 and 24 h of inflam-
mation (Fig. 2). Myeloid lineage cells showed significant
reduction in recruitment after 4 h (
 
z
 
55%) and 24 h
(
 
z
 
70%), whereas T lineage cells were hardly affected by
the absence of uPAR after 4 h, but showed significant in-
hibition in emigration (
 
z
 
60%) after 24 h (Fig. 2). Consis-
tently, administration of mAbs demonstrated that lymphocyte
recruitment after 4 h was largely independent of LFA-
1–ICAM-1 interactions in contrast to recruitment after 24 h
of inflammation.
To further specify those granulocytic subpopulations that
were mostly affected, a differential cell staining (May-
Grünwald-Giemsa) was performed (Fig. 3). In uPAR-defi-
cient mice, after 4 h, neutrophil and eosinophil recruitment
was inhibited by .70% or 90%, respectively, and residual
emigration was marginally affected by the administration of
mAbs against ICAM-1 or LFA-1, respectively. In contrast,
in wild-type mice the recruitment of these two cell types
was effectively blocked by these antibodies down to the
level of emigrated cells in uPAR2/2 mice, suggesting that
Figure 1. Leukocyte emigra-
tion in thioglycollate-induced
peritonitis.  Wild-type mice (white
bars) and uPAR-deficient mice
(black bars) were injected intra-
peritoneally with buffer alone
(Control) or with thioglycollate
solution in the absence or pres-
ence of the indicated antibodies.
After leukocyte emigration for
4 h, mice were killed and the leukocytes were counted in lavages from
the peritoneum. SE was calculated from four animals for each condition
and the experiment was repeated twice. #P , 0.02; *P , 0.01.1032 Urokinase Receptor and b2 Integrin Function
leukocyte recruitment in uPAR-deficient mice is dimin-
ished through impaired function of the b2 integrin/ICAM-1
system. Basophil emigration into the inflamed peritoneum
was not significantly affected in uPAR-deficient mice but
was comparable to that in wild-type mice receiving anti–
ICAM-1 or anti–LFA-1 mAb, respectively. Thus, the de-
finitive role of uPAR for basophil recruitment is not yet
clear and requires further investigation. Comparable find-
ings for granulocyte subpopulations were noted after 24 h of
inflammation (data not shown). These data provide in vivo
evidence for a functional consequence of the uPAR/b2 in-
tegrin system in leukocyte adhesion/migration and present
a new phenotype for uPAR-deficient mice.
Requirement of uPAR for Leukocyte Adhesion to Endothelium
In Vitro. uPAR is expressed on circulating human blood
cells, such as granulocytes, monocytes, and activated T
cells. The human myelo-monocytic cell lines HL60 and
U937 differentiate into mononuclear phagocyte–like cells
after treatment with vitamin D3 and transforming growth
factor b1 (31). This in vitro differentiation induced the ex-
pression of a monocyte-specific antigen pattern including
the molecules CD14, CD11b, CD18, and CD87 (uPAR)
as measured by flow cytometry (data not shown). Adhesion
of these differentiated monocytic cells to endothelial cell
monolayers was induced six- to eightfold by PMA or
Mn21, both reagents known for their activation of b2 inte-
grins. The mAb 60.3 directed against the b2 integrin chain
blocked adhesion by 75–85% in both cases, indicating that
leukocyte adhesion to endothelium was b2 integrin depen-
dent (Fig. 4).
Pretreatment of leukocytes with piPLC removed z80%
of uPAR from the cell surface as assessed by flow cytome-
try (data not shown). This resulted in a 70–80% reduction
of PMA-induced or a 65–70% reduction of Mn21-induced
leukocyte adhesion (Fig. 4). Reconstitution of the uPAR-
depleted cells with intact soluble uPAR for 10 min restored
adhesion to the level as observed with untreated cells. This
restoration of uPAR-induced adhesion was abrogated by anti-
CD18 antibody, indicating that the b2 integrin–dependent
adhesion was inducible by uPAR.
In a dose-dependent manner, intact soluble uPAR in-
creased adhesion of piPLC-treated leukocytes to endothe-
lium to maximal levels, whereas addition of the truncated
form of uPAR lacking the uPA binding domain D1 did
not, indicating a specific structural requirement for b2 inte-
grin activation (Fig. 5). In contrast to PMA, which induces
both increased surface expression and activation of b2 inte-
grins, flow cytometric analysis revealed no change in inte-
Figure 2. Analysis of subpopulations of emigrated leukocytes in the
peritoneal lavage. Leukocytes obtained in peritoneal lavages after induc-
tion of peritonitis for 4 (A) or 24 h (B) from wild-type mice (white bars)
and uPAR-deficient mice (black bars) were analyzed by flow cytometry
for the expression of Gr-1 (anti-granulocytes), Mac-1 (anti-myeloid cells),
or CD3 (anti-CD3 TCR complex). Absolute numbers of cells were cal-
culated from the percentage of stained cells and the number of total emi-
grated cells shown in Fig. 1. #P , 0.01; *P , 0.002; §P , 0.005.
Figure 3. Quantitation of gran-
ulocyte  subpopulations in the
peritoneal lavage. The migrated
leukocytes from wild-type mice
(white bars) and uPAR-deficient
mice (black bars) were cytocentri-
fuged and stained with May-
Grünwald-Giemsa solution. The
quantitation of cell numbers of
leukocyte subpopulations was
performed by light microscopy.
SE was calculated from four ani-
mals for each condition and the
experiment was repeated twice.
#P , 0.02; *P , 0.005.
Figure 4. Requirement of
uPAR for leukocyte adhesion to
endothelial cells. Myelo-mono-
cytic HL60 cells were either not
treated (hatched bars) or pre-
treated with piPLC (0.5 U/ml,
90 min, 378C; black bars),
washed, and incubated for 10
min without or with soluble in-
tact uPAR (0.8 mg/ml), fol-
lowed by stimulation for 20 min
with (A) PMA (10 ng/ml) or (B)
Mn21 (1 mM). After another
washing step, the adhesion assay
was performed in the absence or
presence of anti–b2 integrin
mAb 60.3 (10 mg/ml). Values
are displayed as percent of PMA-
or Mn21-inducible adhesion and
represent the mean 6 SEM of
three independent experiments.
*P , 0.001 as compared with
control.1033 May et al.
grin expression after Mn21 treatment (data not shown), as
previously described (8). Likewise, removal of uPAR did
not affect surface expression of the aL, aM, or b2 chain of
the integrins in resting or stimulated cells as analyzed by
flow cytometry (data not shown). Thus, the presence of
uPAR appears to support adhesion by regulating integrin
function rather than by quantitatively changing b2 integrin
levels on the cell surface.
Anti-uPAR mAb No. 3936 Induces Leukocyte Adhesion to En-
dothelial and Smooth Muscle Cells via b2 Integrins. Since uPAR
is directly involved in b2 integrin–mediated leukocyte ad-
hesion to the endothelium, we examined the consequences
of uPAR occupancy on leukocyte adhesion to endothelial
cells using different mAbs against uPAR. Preincubation
with the anti-uPAR mAb no. 3936 resulted in the six- to
eightfold increase of cell adhesion reaching the same maxi-
mal level as achieved with PMA or Mn21 (Fig. 6). For un-
differentiated HL60 or U937 cells, which show low surface
expression of b2 integrins and uPAR, respectively, the acti-
vating anti-uPAR mAb increased adhesion only 1.5–2-fold
(data not shown). Boiling of the antibody totally abrogated
its adhesion-stimulating effect. In addition, (Fab9)2 frag-
ments of mAb no. 3936 had a very similar proadhesive ef-
fect as compared with the intact mAb. Control isotype–
matched mAb IgG2a as well as other anti-uPAR mAbs di-
rected against different epitopes of uPAR did not induce leu-
kocyte adherence. The dose- and time-dependent kinetics
of antibody ligation suggested that the uPAR–mAb com-
plex serves as a fast and effective trigger of b2 integrin acti-
vation (Fig. 7). In contrast, the anti-uPAR mAb R3 that
has the same inhibitory effect on uPA binding to the recep-
tor as mAb no. 3936 was not able to promote leukocyte
adhesion. The anti-uPAR mAbs did not significantly
change  b2 integrin expression (data not shown), indicating
that a functional conformational change of the adhesion re-
ceptor is responsible for the proadhesive effect.
Analogous to PMA- or Mn21-induced b2 integrin–depen-
dent  cell adhesion, mAb 60.3 could abrogate mAb no.
3936–induced leukocyte adhesion to cultured endothelial
and smooth muscle cells, indicating b2 integrin dependency
(Fig. 8). In addition, vitamin D3/transforming growth fac-
tor b1 differentiated U937 cells and freshly isolated periph-
eral blood neutrophils responded to mAb no. 3936 in an
identical manner, emphasizing that this functional interac-
tion of uPAR with b2 integrins occurs in different cell
populations such as monocytes and neutrophils.
Occupancy of uPAR by uPA Reduces b2 Integrin Activation–
dependent Leukocyte Adhesion to Endothelium. Although the ad-
dition of exogenous uPA, the natural ligand of uPAR, had
no effect on background adhesion, uPA significantly inhib-
ited b2 integrin–mediated adhesion in response to any of
the three described stimulating pathways (Fig. 9); adhesion
of leukocytes to endothelium achieved by cell activation
Figure 5. Reconstitution of leukocyte adhesion to endothelium by sol-
uble uPAR. Adhesion of monocytic cells to HUVECs was performed as
described in the legend to Fig. 4. piPLC-pretreated myelo-monocytic
HL60 cells were incubated with increasing concentrations of soluble in-
tact (D1/D2/D3) uPAR or with its truncated form (D2/D3) lacking do-
main 1, respectively, and were subsequently stimulated by PMA. Values
are displayed as percentage of PMA-inducible adhesion in non–piPLC-
pretreated cells and one representative experiment out of three is shown.
#P , 0.01 and *P , 0.001 as compared with piPLC-pretreated cells
without soluble uPAR.
Figure 6. Effect of different
anti-uPAR mAbs on leukocytic
cell adhesion to endothelium.
Myelo-monocytic HL60 cells
were incubated for 30 min with
different anti-uPAR mAbs (20
mg/ml each) representing uPA-
blocking (no. 3936, R3, R9) or
-nonblocking (R2, R4, R8) ac-
tivity, with (Fab9)2 of mAb no.
3936 (12 mg/ml), boiled (5 min)
mAb no. 3936, or control IgG2a
as indicated. After washing, the
adhesion assay was performed.
Values are displayed as percent-
age of control (no antibody
added) and represent the mean
(6 SEM) of at least three inde-
pendent experiments. *P ,
0.001 as compared with control.
Figure 7. Induction of leukocyte adhesion to endothelium by anti-
uPAR mAb no. 3936. Anti-uPAR mAb no. 3936 (j) or R3 (u) were
added to myelo-monocytic HL60 cells for 1 h at different concentrations
(A), or at a concentration of 10 mg/ml for different time intervals (B).
After washing, the adhesion assay was performed as described. Values
(mean  6 SEM, n 5 3) are displayed as percentage of control (no antibody
added). One representative experiment out of three is shown. *P , 0.001
as compared with control (no antibody added or time 0).1034 Urokinase Receptor and b2 Integrin Function
via PMA, direct extracellular integrin activation via Mn21,
or uPAR ligation by the activating mAb no. 3936 was in-
hibited by active (data not shown) as well as by enzymati-
cally inactive uPA. Thus, uPA binding to uPAR indepen-
dent of its catalytic activity appears to control b2 integrin
activation irrespective of the integrin-activating stimulus.
Since uPA or its inactivated isoform did not alter the sur-
face expression of the integrin aL, aM, or b2 chain in ei-
ther resting or stimulated cells (data not shown), we pro-
pose that the binding of uPA to uPAR prevents the
induction of conformational change(s) leading to b2 inte-
grin activation.
Discussion
The major contribution of b2 integrins in immune de-
fense and inflammatory processes relates to their pivotal
role in mediating cellular contacts between leukocytes and
endothelium as a prerequisite for subsequent transmigration
towards a chemotactic stimulus. Previous in vitro studies
have demonstrated that uPAR forms complexes with inte-
grins (12, 13) and thereby modulates integrin-mediated bind-
ing to extracellular matrix proteins (26–28).
This study demonstrates that uPAR is needed for b2 in-
tegrin–dependent leukocyte recruitment into sites of acute
inflammation. Migration of neutrophils and monocytes
into the inflamed peritoneum was drastically reduced after
4 h in uPAR-deficient mice. Consistently, b2 integrin–
dependent cell adhesion of leukocytes to endothelial cells
was abrogated after depletion of uPAR from the cell sur-
face, whereas reconstitution with soluble intact, but not
truncated, uPAR could totally rescue b2 integrin–mediated
adhesion. Regulation of b2 integrin activity probably in-
volves uPAR domain 1, since occupancy by a mAb that
blocks uPA-binding to this domain strongly induced leu-
kocyte adhesion to vascular endothelial cells, whereas uPA
itself inhibited b2 integrin–dependent adhesion.
The adhesion of leukocytes to inflamed vascular endo-
thelium and the transendothelial migration largely depend
on the activation of b2 integrins and binding to its counter-
receptor ICAM-1 (41, 42), as evidenced by inhibition and
gene-targeting studies (40, 43, 44). Although b2 integrin
complexes are essential to neutrophil emigration, recent re-
sults from b2-deficient mice demonstrated that Mac-1/
LFA-1–independent pathways for cell recruitment can be
used during acute inflammation in the peritoneum and the
lung (45).
In this study, a new phenotype for uPAR-deficient mice
is described that is similar to that of wild-type animals after
treatment with inhibiting antibodies against the vascular b2
integrin LFA-1 and its ligand ICAM-1. Further blockade
with mAbs of leukocyte migration in uPAR2/2 mice was
marginal, suggesting that the function of the b2 integrin/
ICAM-1 adhesion system was blocked by the absence of
uPAR. This strongly suggests that leukocyte recruitment to
the acutely inflamed peritoneum requires the uPAR. In
fact, under conditions of acute inflammation the phenotype
of uPAR mice resembles that of ICAM-1– or aL-deficient
mice (40, 46).
In accordance with the known role of b2 integrins for
the acute and early inflammatory responses, reduced leuko-
cyte infiltration in uPAR2/2 mice was observed after short-
term inflammation for 4 or 24 h. It was shown previously
that the total number of migrated leukocytes in uPAR2/2
mice was not affected after long-term inflammation for 3 d
(47). This may be due to the fact that prolonged inflamma-
tion upregulates and activates several other adhesion recep-
tor systems on leukocytes and vascular cells apart from b2
integrins, such as b1 and b7 integrins, vascular cell adhesion
molecule 1, or addressins, all of which contribute to leuko-
cyte recruitment (1). Especially after long-term inflamma-
tion, the a4b1 integrin may substitute for b2 integrins. The
finding that migration of granulocytes that do not express
a4b1 integrin was mainly affected by the absence of the
uPAR further supports this concept.
Recent in vitro studies have shown that the presence of
uPAR is needed for Mac-1 binding to fibrinogen (27), and
it also regulates fibrinogen degradation by forming a func-
tional unit with the b2 integrin (28). Consistently, b2 inte-
grin–dependent cell-to-cell adhesion required the presence
of endogenous or exogenously added intact (soluble) uPAR
in vitro. In the absence of uPAR, neither PMA nor Mn21
induction of piPLC-treated leukocytes was sufficient to al-
low adhesion, indicating a superior regulatory function for
Figure 8. Induction of leuko-
cyte adhesion to endothelial and
smooth muscle cells by anti-
uPAR mAb no. 3936. Myelo-
monocytic HL60 cells (black bars),
monocytic U937 cells (hatched
bars) and freshly isolated neutro-
phils (white bars) were pretreated
with anti-uPAR mAb no. 3936
(20 mg/ml) for 30 min. After
washing, the adhesion assay was
performed in the absence or
presence of anti–b2 integrin mAb
60.3 or isotype control mAb (10
mg/ml) as indicated. Values
(mean  6 SEM, n 5 3) are dis-
played as percentage of control
(no antibody added), and one
representative experiment out of three is shown. *P , 0.001 as compared
with anti-uPAR-induced adhesion.
Figure 9. Interference of uPA
with leukocyte adhesion to en-
dothelium. Myelo-monocytic
HL60 cells were incubated in the
absence (hatched bars) or the pres-
ence (black bars) of inactivated
uPA (50 nM) for 30 min (378C,
5% CO2) before addition of me-
dium, PMA (10 ng/ml), Mn21
(1.0 mM), or anti-uPAR mAb
no. 3936 (10 mg/ml) for another
30 min, as indicated. After wash-
ing, the adhesion assay was performed. Values are displayed as percent of
untreated control (medium) and represent the mean 6 SEM of three inde-
pendent experiments. *P , 0.01.1035 May et al.
uPAR regardless of the stimulatory pathway. Moreover,
the intact (soluble) uPAR appears to be crucial in the cross-
talk with b2 integrins (Fig. 10), implying direct binding in-
teractions between these two receptors as was demon-
strated in an isolated system for Mac-1 (26). In contrast, the
truncated form of uPAR was ineffective, and uPA itself sig-
nificantly inhibited cell-to-cell adhesion, suggesting that
domain 1 of uPAR is predominantly involved in b2 inte-
grin activation. A similar inhibitory effect of uPA on b2 in-
tegrin function has previously been proposed with regard
to Mac-1–mediated fibrinogen binding and degradation
(27, 28).
Although uPAR-dependent proteolytic activity did not
seem to be critical for leukocyte recruitment (47), the fo-
calized proteolytic activity of the uPAR–uPA complex is
tightly correlated with the migratory or invasive potential
of cells in a variety of biological systems (48). On the other
hand, active uPA has been found to support cell migration
in vitro via proteolysis or cell-activating processes and was
required for adequate leukocyte recruitment into the lungs
and a subsequent inflammatory response after 3 wk of fun-
gal infection (49). Collectively, our combined in vivo and
in vitro studies together with previous reports strongly in-
dicate that proteolysis-independent cross-talk of uPAR
with  b2 integrins occurs in the initial phase of leukocyte in-
teraction with the vessel wall, whereas subsequent recruit-
ment into inflamed tissue may require proteolysis-depen-
dent mechanisms including plasmin action.
uPAR appeared to induce and facilitate b2 integrin acti-
vation on its own when stimulated by the specific anti-
uPAR mAb no. 3936 or its (Fab9)2 fragment. Although
cross-linking of uPAR cannot be ruled out, this antibody
provides an additional stimulatory pathway for b2 integrin
engagement. In accordance with this concept, uPA was
found to interfere by either competing for mAb no. 3936
binding or by not allowing integrin activation to occur as
pointed out before. Since removal of cell surface–associated
uPA by acidic wash (data not shown) and the use of other
antibodies that also block uPA binding to uPAR (such as
R3) did not affect cell adhesion, we attribute the proadhe-
sive capability of mAb no. 3936 to its specific ligation of
uPAR rather than to competition with endogenous uPA.
In contrast to our findings that the mAb no. 3936 induces
b2 integrin–dependent cell-cell adhesion, Mac-1–medi-
ated leukocyte adhesion to fibrinogen has been shown to
be inhibited by the anti-uPAR mAb 3B10 (27). These di-
verse findings may be due to the experimental systems used
and/or to the different integrins or ligands involved. Al-
though vitronectin and PAI-1 are known to regulate
uPAR as well as av integrin–dependent cell-substrate ad-
hesion (50–52), both factors did not interfere with b2 inte-
grin–dependent cell–cell adhesion (data not shown), un-
derlining the specificity of the uPAR system in this regard.
Our findings indicate that uPAR plays a major role for
leukocyte adhesion. Nevertheless, patients with paroxysmal
nocturnal hemoglobinuria (PNH) lacking cell-bound uPAR
and other cell surface proteins due to a defective production
of glycolipid anchors do not necessarily show an enhanced
susceptibility for infections, whereas isolated neutrophils
from these patients are impaired in their transendothelial
migration in vitro (53). Possible explanations might be that
(a) in PNH, which is an acquired clonal disease, a portion
of the cells remains unaffected and may therefore be suffi-
cient for host defense as demonstrated in the experiments
with uPAR-deficient mice; or (b) circulating soluble uPAR
is enhanced three- to fourfold in PNH patients (54) and
might be sufficient for b2 integrin function in vivo in these
patients, as documented here in vitro. The present observa-
tions indicate that uPAR controls integrin-mediated inter-
actions in vitro as well as in vivo, and these findings might
have therapeutic consequences for the treatment of hyper-
inflammatory or invasive processes related to vascular or
immune diseases.
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Figure 10. Hypothetical model for the uPAR–b2 integrin cross-talk.
The presence of uPAR on leukocyte subpopulations is required for their
adhesion to endothelium and their subsequent recruitment into the in-
flamed tissue as documented here for a peritonitis model. In vitro, ligation
of uPAR by a specific mAb no. 3936 induces leukocyte adhesion to en-
dothelial cells, whereas uPA greatly inhibits cell-to-cell interactions inde-
pendent of the stimulatory pathway.1036 Urokinase Receptor and b2 Integrin Function
Address correspondence to Klaus T. Preissner, Haemostasis Research Unit, Max-Planck-Institute, Kerck-
hoff-Klinik, Sprudelhof 11, D-61231 Bad Nauheim, Germany. Phone: 49-603-299-6719; Fax: 49-603-299-
6707; E-mail: klaus.t.preissner@kerckhoff.med.uni-giessen.de
Received for publication 5 February 1998 and in revised form 12 May 1998.
References
1. Springer, T.A. 1994. Traffic signals for lymphocyte recircula-
tion and leukocyte emigration: the multistep paradigm. Cell.
76:301–314.
2. Carlos, T.M., and J.M. Harlan. 1994. Leukocyte-endothelial
adhesion molecules. Blood. 84:2068–2101.
3. Larson, R.S., and T.A. Springer. 1990. Structure and func-
tion of leukocyte integrins. Immunol. Rev. 114:181–217.
4. Van der Vieren, M., H. Le Trong, C.L. Wood, P.F. Moore,
T. St. John, D.E. Staunton, and W.M. Gallatin. 1995. A
novel leukointegrin, adb2, binds preferentially to ICAM-3.
Immunity. 3:683–690.
5. Smith, C.W., S.D. Marlin, R. Rothlein, C. Toman, and
D.C. Anderson. 1989. Cooperative interactions of LFA-1
and Mac-1 with intercellular adhesion molecule-1 in facilitat-
ing adherence and transendothelial migration of human neu-
trophils in vitro. J. Clin. Invest. 83:2008–2017.
6. Lu, H., C.W. Smith, J. Perrard, D. Bullard, L.P. Tang, S.B.
Shappell, M.L. Entman, A.L. Beaudet, and C.M. Ballantyne.
1997. LFA-1 is sufficient in mediating neutrophil emigration
in MAC-1–deficient mice. J. Clin. Invest. 99:1340–1350.
7. Miller, L.J., D.F. Bainton, N. Borregaard, and T.A. Springer.
1987. Stimulated mobilization of monocyte Mac-1 and
p150,95 adhesion proteins from an intracellular vesicular
compartment to the cell surface. J. Clin. Invest. 80:535–544.
8. Altieri, D.C. 1991. Occupancy of CD11b/CD18 (Mac-1) di-
valent ion binding site(s) induces leukocyte adhesion. J. Im-
munol. 147:1891–1898.
9. Couffinhal, T., C. Duplaa, C. Moreau, J.-M.D. Lamaziere,
and J. Bonnet. 1994. Regulation of vascular cell adhesion
molecule-1 and intercellular adhesion molecule-1 in human
vascular smooth muscle cells. Circ. Res. 74:225–234.
10. Skubitz, K.M., K.D. Campbell, J. Iida, and A.P.N. Skubitz.
1996. CD63 associates with tyrosine kinase activity and
CD11/CD18, and transmits an activation signal in neutro-
phils. J. Immunol. 157:3617–3626.
11. Zhou, M., R.F. Todd III, J.G. van de Winkel, and H.R.
Petty. 1993. Cocapping of the leukoadhesin molecules com-
plement receptor type 3 and lymphocyte function–associated
antigen-1 with Fcg receptor III on human neutrophils. Possi-
ble role of lectin-like interactions. J. Immunol. 150:3030–
3038.
12. Bohuslav, J., V. Horejsí, C. Hansmann, J. Stöckl, U.H. Wei-
dle, O. Majdic, I. Bartke, W. Knapp, and H. Stockinger.
1995. Urokinase plasminogen activator receptor, b2-inte-
grins, and Src-kinases within a single receptor complex of
human monocytes. J. Exp. Med. 181:1381–1390.
13. Xue, W., A.L. Kindzelskii, R.F. Todd III, and H.R. Petty.
1994. Physical association of complement receptor type 3 and
urokinase-type plasminogen activator receptor in neutrophil
membranes. J. Immunol. 152:4630–4640.
14. Ploug, M., E. Ronne, N. Behrendt, A.L. Jensen, F. Blasi, and
K. Dano. 1991. Cellular receptor for urokinase plasminogen
activator. Carboxyl-terminal processing and membrane an-
choring by glycosyl-phosphatidylinositol. J. Biol. Chem. 266:
1926–1933.
15. Hoyer-Hansen, G., E. Ronne, H. Solberg, N. Behrendt, M.
Ploug, L.R. Lund, V. Ellis, and K. Dano. 1992. Urokinase
plasminogen activator cleaves its cell surface receptor releas-
ing the ligand-binding domain. J. Biol. Chem. 267:18224–
18229.
16. Kanse, S.M., C. Kost, O.G. Wilhelm, P.A. Andreasen, and
K.T. Preissner. 1996. The urokinase receptor is a major vit-
ronectin binding protein on endothelial cells. Exp. Cell Res.
224:344–353.
17. Chapman, H.A. 1997. Plasminogen activators, integrins, and
the coordinated regulation of cell adhesion and migration.
Curr. Opin. Cell Biol. 9:714–724.
18. Cao, D., I.F. Mizukami, B.A. Garni-Wagner, A.L. Kindzel-
skii, R.F. Todd III, L.A. Boxer, and H.R. Petty. 1995. Hu-
man urokinase-type plasminogen activator primes neutrophils
for superoxide anion release. Possible roles of complement
receptor type 3 and calcium. J. Immunol. 154:1817–1829.
19. Dumler, I., T. Petri, and W.-D. Schleuning. 1993. Interac-
tion of urokinase-type plasminogenactivator (u-PA) with its
cellular receptor (u-PAR) induces phosphorylation on ty-
rosine of a 38 kDA protein. FEBS Lett. 322:37–40.
20. Busso, N., S.K. Masur, D. Lazega, S. Waxman, and L. Os-
sowski. 1994. Induction of cell migration by pro-urokinase
binding to its receptor: possible mechanism for signal trans-
duction in human epithelial cells. J. Cell Biol. 126:259–270.
21. Resnati, M., M. Guttinger, S. Valcamonica, N. Sidenius, F.
Blasi, and F. Fazioli. 1996. Proteolytic cleavage of the uroki-
nase receptor substitutes for the agonist-induced chemotactic
effect. EMBO (Eur. Mol. Biol. Organ.) J. 15:1572–1582.
22. Rao, N.K., G.-P. Shi, and H.A. Chapman. 1995. Urokinase
receptor is a multifunctional protein: influence of receptor
occupancy on macrophage gene expression. J. Clin. Invest.
96:465–474.
23. Petty, H.R., and R.F. Todd III. 1996. Integrins as promiscu-
ous signal transduction devices. Immunol. Today. 17:209–212.
24. Pöllänen, J., R.W. Stephens, and A. Vaheri. 1991. Directed
plasminogen activation at the surface of normal and malig-
nant cells. Adv. Cancer Res. 57:273–328.
25. Gyetko, M.R., R.F. Todd III, C.C. Wilkinson, and R.G.
Sitrin. 1994. The urokinase receptor is required for human
monocyte chemotaxis in vitro. J. Clin. Invest. 93:1380–1387.
26. Wei, Y., M. Lukashev, D.I. Simon, S.C. Bodary, S. Rosen-
berg, M.V. Doyle, and H.A. Chapman. 1996. Regulation of
integrin function by the urokinase receptor. Science. 273:
1551–1555.
27. Sitrin, R.G., R.F. Todd III, H.R. Petty, T.G. Brock, S.B.
Shollenberger, E. Albrecht, and M.R. Gyetko. 1996. The
urokinase receptor (CD87) facilitates CD11B/CD18-medi-
ated adhesion of human monocytes. J. Clin. Invest. 97:1942–
1951.
28. Simon, D.I., N.K. Rao, H. Xu, Y. Wei, O. Majdic, O.1037 May et al.
Ronne, L. Kobzik, and H.A. Chapman. 1996. Mac-1
(CD11b/CD18) and the urokinase receptor (CD87) form a
functional unit on monocytic cells. Blood. 88:3185–3194.
29. Behrendt, N., E. Ronne, M. Ploug, T. Petri, D. Lober, L.S.
Nielsen, W.-D. Schleuning, F. Blasi, E. Appella, and K.
Dano. 1990. The human receptor for urokinase plasminogen
activator. NH2-terminal amino acid sequence and glycosyla-
tion variants. J. Biol. Chem. 265:6453–6460.
30. Behrendt, N., M. Ploug, L. Patthy, G. Houen, F. Blasi, and
K. Dano. 1991. The ligand-binding domain of the cell sur-
face receptor for urokinase-type plasminogen activator. J.
Biol. Chem. 266:7842–7847.
31. Waltz, D.A., L.Z. Sailor, and H.A. Chapman. 1993. Cyto-
kines induce urokinase-dependent adhesion of human mye-
loid cells. A regulatory role for plasminogen activator inhibi-
tors. J. Clin. Invest. 91:1541–1552.
32. Mizukami, I.F., S.D. Vinjamuri, R.D. Trochelman, and R.F.
Todd III. 1990. A structural characterization of the uPA-R
activation antigen expressed on the plasma membrane of hu-
man mononuclear phagocytes. J. Immunol. 146:1841–1848.
33. Ronne, E., N. Behrendt, V. Ellis, M. Ploug, K. Dano, and
G. Hoyer-Hansen. 1991. Cell-induced potentiation of the
plasminogen activation system is abolished by a monoclonal
antibody that recognizes the NH2-terminal domain of the
urokinase receptor. FEBS Lett. 288:1–2.
34. Wallis, W.J., D.D. Hickstein, B.R. Schwartz, C.H. June,
H.D. Ochs, P.G. Beatty, S.J. Klebanoff, and J.M. Harlan.
1986. Monoclonal antibody–defined functional epitopes on
the adhesion-promoting glycoprotein complex (CDw18) of
human neutrophils. Blood. 67:1007–1013.
35. Sanchez-Madrid, F., P. Simon, S. Thompson, and T.A.
Springer. 1983. Mapping of antigenic and functional epitopes
on the a and b subunits of two related mouse glycoproteins
involved in cell interactions, LFA-1 and Mac-1. J. Exp. Med.
158:586–602.
36. Prieto, J., F. Takei, R. Gendelman, B. Christenson, P. Biber-
feld, and M. Patarroyo. 1989. MALA-2, mouse homologue
of human adhesion molecule ICAM-1 (CD54). Eur. J. Immu-
nol. 19:1551–1557.
37. Jaffe, E.A., R.L. Nachman, C.G. Becker, and C.R. Minick.
1973. Culture of human endothelial cells derived from um-
bilical veins. J. Clin. Invest. 52:2745–2756.
38. Kanse, S.M., E. Wijelath, C. Kanthou, P. Newman, and
V.V. Kakkar. 1995. The proliferative responsiveness of hu-
man vascular smooth muscle cells to endothelin correlates
with endothelin receptor density. Lab. Invest. 72:376–382.
39. Bugge, T.H., T.T. Suh, M.J. Flick, C.C. Daugherty, J.
Romer, H. Solberg, V. Ellis, K. Dano, and J.L. Degen. 1995.
The receptor for urokinase-type plasminogen activator is not
essential for mouse development or fertility. J. Biol. Chem.
270:16886–16894.
40. Sligh, J.E., C.M. Ballantyne, S.S. Rich, H.K. Hawkins, C.W.
Smith, A. Bradley, and A.L. Beaudet. 1993. Inflammatory
and immune responses are impaired in mice deficient in in-
tercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA.
90:8529–8533.
41. Oppenheimer-Marks, N., and P.E. Lipsky. 1993. The adhe-
sion and trans-endothelial migration of human T lymphocyte
subsets. Behring Inst. Mitt. 92:44–50.
42. Hogg, N., and C. Berlin. 1995. Structure and function of ad-
hesion receptors in leukocyte trafficking. Immunol. Today. 16:
327–330.
43. Anderson, D.C., and T.A. Springer. 1987. Leukocyte adhe-
sion deficiency: an inherited defect in the Mac-1, LFA-1 and
p150/95 glycoprotein. Annu. Rev. Med. 38:175–194.
44. Kuijpers, T.W., and J.M. Harlan. 1993. Monocyte-endothe-
lial interactions: insights and questions. J. Lab. Clin. Med.
122:641–651.
45. Mizgerd, J.P., H. Kubo, G.J. Kutkoski, S.D. Bhagwan, K.
Scharffetter-Kochanek, A.L. Beaudet, and C.M. Doerschuk.
1997. Neutrophil emigration in the skin, lungs, and perito-
neum: different requirements for CD11/CD18 revealed by
CD18-deficient mice. J. Exp. Med. 186:1357–1364.
46. Schmits, R., T.M. Kündig, D.M. Baker, G. Shumaker, J.J.L.
Simard, G. Duncan, A. Wakeham, A. Shahinian, A. van der
Heiden, M.F. Bachmann, et al. 1996. LFA-1–deficient mice
show normal CTL responses to virus but fail to reject immu-
nogenic tumor. J. Exp. Med. 183:1415–1426.
47. Dewerchin, M., A. Van Nufelen, G. Wallays, A. Bouche, L.
Moons, P. Carmeliet, R.C. Mulligan, and D. Collen. 1996.
Generation and characterization of urokinase receptor–defi-
cient mice. J. Clin. Invest. 97:870–878.
48. Kirchheimer, J.C., and H.G. Remold. 1989. Endogenous re-
ceptor-bound urokinase mediates tissue invasion of human
monocytes. J. Immunol. 143:2634–2639.
49. Gyetko, M.R., G.-H. Chen, R.A. McDonald, R. Goodman,
G.B. Huffnagle, C.C. Wilkinson, J.A. Fuller, and G.B.
Toews. 1996. Urokinase is required for the pulmonary in-
flammatory response to Cryptococcus neoformans. J. Clin. Invest.
97:1818–1826.
50. Stefansson, S., and D.A. Lawrence. 1996. The serpin PAI-1
inhibits cell migration by blocking integrin avb3 binding to
vitronectin. Nature. 383:441–443.
51. Deng, G., S.A. Curriden, S. Wang, S. Rosenberg, and D.J.
Loskutoff. 1996. Is plasminogen activator inhibitor-1 the mo-
lecular switch that governs urokinase receptor–mediated cell
adhesion and release? J. Cell Biol. 134:1563–1571.
52. Kjoller, L., S.M. Kanse, T. Kierkegaard, K.W. Rodenburg,
E. Ronne, S.L. Goodman, K.T. Preissner, L. Ossowski, and
P.A. Andreasen. 1997. Plasminogen activator inhibitor-1 re-
presses integrin- and vitronectin-mediated cell migration in-
dependently of its function as an inhibitor of plasminogen ac-
tivation. Exp. Cell Res. 232:420–429.
53. Pedersen, T.L., K. Yong, J.O. Pedersen, N.E. Hansen, K.
Dano, and T. Plesner. 1996. Impaired migration in vitro of
neutrophils from patients with paroxysmal nocturnal haemo-
globinuria. Brit. J. Haematol. 95:45–51.
54. Poston, R.N., D.O. Haskard, J.R. Coucher, N.P. Gall, and
R.R. Johnson-Tidey. 1992. Expression of intercellular adhe-
sion molecule-1 in atherosclerotic plaques. Am. J. Pathol.
140:665–673.